Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 71.1%

Neg 0% Neu 0% Pos 71.1%

Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.